Feline Immunodeficiency Virus gp95 antibody | SU1-30
The primary receptor for FIV infection of cats has been identified as the T-cell activation antigen CD134 which, along with CXC chemokine receptor 4 (CXCR4), facilitates the infection of CD4+ primary target cells, resulting in a depletion in the CD4+ population. Studies have shown that the V3 loop of SU,gp95 is a major immunogenic domain, suggested to contain the main determinants for the binding of FIV SU,gp95 to CXCR4 (Sundstrom, M. et al. 2008).
Mouse anti Feline Immunodeficiency Virus gp95 antibody, clone SU1-30 has been shown to inhibit the sCD134-activated entry of both clade B and clade C FIV strains (de Parseval, A. et al. 2006).
Mouse anti Feline Immunodeficiency Virus gp95 antibody, clone SU1-30 does not recognise Feline Leukaemia Virus, Feline Herpes Virus type 1, Feline Coronavirus or Feline Calicivirus.
Removal of Sodium Azide is recommended prior to use in functional studies - The use of EQU003 is recommended for this purpose.
- Target Species
- Product Form
- Purified IgG - liquid
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
0.05% Sodium Azide (NaN3)
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- 18 months from date of despatch
- For research purposes only
Applications of Feline Immunodeficiency Virus gp95 antibody
|Application Name||Verified||Min Dilution||Max Dilution|
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul
- Western Blotting
- MCA2552 detects a band of approximately 95kDa under reducing conditions
Secondary Antibodies Available
|Description||Product Code||Applications||Pack Size||List Price||Quantity|
|Rabbit F(ab')2 anti Mouse IgG:RPE||STAR12A||F||1 ml|
|Rabbit F(ab')2 anti Mouse IgG:HRP (Human Adsorbed)||STAR13B||C E P RE WB||1 mg|
|Rabbit F(ab')2 anti Mouse IgG:FITC||STAR9B||F||1 mg|
Product Specific References
References for Feline Immunodeficiency Virus gp95 antibody
DeParseval, A. et al. (2006) Sequential CD134-CXCR4 interactions in feline immunodeficiency virus (FIV): soluble CD134 activates FIV Env for CXCR4-dependent entry and reveals a cryptic neutralization epitope.
J Virol. 80 (6): 3088-91.
Sundstrom, M. et al. (2008) Mapping of the CXCR4 binding site within variable region 3 of the feline immunodeficiency virus surface glycoprotein.
J Virol. 82 (18): 9134-42.
Klonjkowski, B. et al. (2009) Gag-specific immune enhancement of lentiviral infection after vaccination with an adenoviral vector in an animal model of AIDS.
Vaccine. 27: 928-39.
Willett, B.J. et al. (2006) Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus.
J Virol. 80 (7): 3386-94.